--> jQuery(window).scroll(function() { checkStick(); }); var mbannerid = '#div-gpt-ad-1563273235586-0'; var mfooterid = '#footermobilebanner'; var dfooterid = '#div-gpt-ad-1563274691467-0'; // Desktop sticky check function checkStick() { var launched = false; if (jQuery(window).height() > 500) { if (!jQuery('#dfp_stickyfooter').hasClass("closed")) { if (jQuery('#dfp_stickyfooter > div').length) { if (!jQuery('#dfp_stickyfooter > div').hasClass("cog-mb-sticky")) { var width = jQuery('#dfp_stickyfooter > div > iframe').width(); var height = jQuery('#dfp_stickyfooter > div > iframe').height(); if (parseInt(width) > 0) { launched = true; jQuery('#dfp_stickyfooter').attr('style', 'height: '+(height+30)+'px;').addClass('opened'); jQuery('#dfp_stickyfooter').append(' '); jQuery('#dfp_stickyfooter > div').addClass('cog-mb-sticky floating footer'); jQuery('#dfp_stickyfooter > div').attr('style', 'position:absolute; bottom:0;'); jQuery('#dfp_stickyfooter svg.close').on('click', function() { jQuery(this).parent().removeClass('opened').addClass('closed'); }); } } } } } if (!launched) { // Ad not ready yet window.setTimeout(checkStick, 250); } } jQuery(document).ready(function() {checkStick();}); -->

This site is intended for health professionals only

Viramune® approved in EU for HIV-1 treatment

teaser

Viramune® (nevirapine) prolonged-release has received approval for use in the EU in combination with other antiretroviral medications for the treatment of HIV-1 infection.

EU approval for the use of one 400 mg tablet once daily for adults and adolescents – and for 50 mg and 100 mg strengths for once-daily treatment of children – is based on results from clinical trials confirming the significant therapeutic benefits of nevirapine when administered in a convenient once-a-day formulation.

The Viramune® XR™ single 400 mg tablet once daily was approved in the USA by the Food and Drug Administration earlier this year.

In clinical trials, the antiviral efficacy of Viramune® prolonged-release tablets was shown to be non-inferior to the older, twice-daily immediate-release (IR) 200mg tablet, with a safety and tolerability profile comparable to nevirapine IR.

“Nevirapine prolonged-release provides physicians and patients with a simplified, once-daily treatment while maintaining the high level of efficacy, comparable tolerability and favourable lipid profile already associated with the nevirapine immediate-release formulation,” said Dr Keikawus Arastéh, Director of Internal Medicine at Vivantes Auguste-Viktoria-Klinikum in Berlin, Germany.

“Switching therapies and a low pill burden can improve treatment adherence, which is often key to treatment success.”

Boehringer Ingelheim

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x